Hexaware bolsters life sciences capability with the integration of HighPoint and Mobiquity

Mid-sized technology service provider Hexaware played a significant role in developing the world’s first FDA-approved digital pill, de-centralizing clinical trials, and co-engineering the human data science cloud. It has since leapfrogged its capabilities across the life sciences value chain by stitching together capabilities from acquisitions Mobiquity (customer experience transformation) and HighPoint Solutions (business technology and strategy for drug development). Our conversation with Hexaware, which took place right after it announced integration of these companies, showcased case studies and the details of the value they delivered to life sciences clients. We handpicked a couple of these case studies that outlined solutions delivering business value and accelerating the delivery of treatments to those in need.

The top four challenges life sciences organizations face today are a lack of centralized governance, poor automation, hiring staff quality, and poor software applications (see Exhibit 1). Hexaware has built solutions helping several life sciences enterprises overcome these challenges.

Exhibit 1: Life sciences organizations face many internal challenges; a lack of centralized data governance tops the list

Sample: HFS Pulse Study 2023; n = 105
Source: HFS Research, 2023

It has more than 10 years of life sciences industry experience and an agile mindset, and it isn’t afraid of taking up innovative projects and bringing them to the market.

Enhanced bid intel improves clinical trial bid results and streamlines governance

Accelerating clinical trials can increase a drug’s speed to market, earning millions of dollars in income while bringing important lifesaving cures to those in most need. Hexaware helped a client overcome contract management and budget negotiations by driving faster decisions through a bid intelligence platform using Salesforce cloud components. This helped a CRO (contract research organization) develop a better pricing strategy to improve profits and make bids more valuable.

Connecting siloed data accelerates the delivery of therapies and drugs

Connecting the front- and back-office information flows to reduce disconnects in siloed data will improve efficiency and accelerate clinical trials. Hexaware integrated virtual trial systems such as virtual patient engagement, eConsent, trial master file, risk-based monitoring, and clinical trial management systems that allowed clients access to real-time data across siloed platforms and faster time-to-market for the virtual trial platform. Its work with a particular client in partnership with IQVIA on clinical trial design, trial startup, and trial conduct and closure brought an approximately 25% improvement in efficiency across all three phases of the clinical trial. Additionally, with IQVIA, it co-engineered the human data sciences cloud.

Behind the scenes of the world’s first FDA-approved digital pill

Digital pills help track and monitor the pill intake for those who rely on daily medication for diseases like schizophrenia and are likely to second guess their medication intake. Hexaware developed the digital pill in collaboration with Otsuka. These digital pills contain an IEM (ingestible event marker) sensor that sends a signal to a wearable Bluetooth patch connected to the patient’s smartphone. Hexaware developed all the software components and supported the entire life cycle of ABILIFY commercial operations.

It guided Otsuka on ethical and regulatory standards, helped get FDA approvals, and created a datahub that helped the pharma go beyond the pill and real-world evidence generation. Hexaware developed a consolidated web-based portal for sharing encrypted data with healthcare providers (HCP), patients, families, and friends to better enable patient support and collaboration. A mobile app to monitor and track medicine intake information, mood, and rest was part of the solution. Hexaware showcased its ability to engineer a first-of-its-kind digital medicine system from clinical development to market access.

The Bottom Line: Streamlining pharma processes and enabling technologies to innovate the delivery of therapies can accelerate curing complex diseases and expand market share.

Hexaware’s integration of life sciences acquisitions indicates it is strengthening its value proposition to life sciences to help them benefit from emerging technologies and innovative solutions beyond the traditional biosciences space. Hexaware has many case studies to showcase its growing life sciences capabilities to address the technology debt and requirements of emerging technologies in the life sciences industry.

Additionally, it should continue to develop more life sciences-specific partnerships and attract experts to develop an effective ecosystem to drive new sources of value for life sciences enterprises.